Preliminary Analysis Of A Us Phase Ii Study Of The Safety And Tolerability Of Proxalutamide (Gt0918) In Subjects With Mcrpc Who Had Progressed On Either Abiraterone (Abi) Or Enzalutamide (Enza).

JOURNAL OF CLINICAL ONCOLOGY(2021)

引用 1|浏览7
暂无评分
摘要
99Background: GT0918, an androgen receptor (AR) antagonist, is a new chemical entity with reduced drug accumulation in the CNS. In a phase I dose escalation trial (NCT02826772), GT0918 was well tol...
更多
查看译文
关键词
Androgen Receptor
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要